Bipolar disorder affects 40-50 million people globally, with genetic heritability between 60-80%, and can be triggered by both positive and negative life events, including promotions or new ...

Bipolar disorder is a complex psychiatric disorder, characterized by fluctuations between episodes of (hypo)mania and ...

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for ...

In the largest genome-wide study of bipolar disorder to date, an international team of psychiatric genetics researchers has ...

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar ...

Antipsychotic medications can help a person with bipolar disorder stabilize their moods, reduce agitation, and improve overall quality of life. Learn more about the medication types, dosage, side ...

2024 — Investigators evaluated whether data collected from a fitness tracker could be used to accurately detect mood episodes in people with bipolar ... Nov. 20, 2024 — Depression is one of ...

Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.

People with bipolar disorder may be at a higher risk of developing premenstrual dysphoric disorder (PMDD), but neither condition directly causes the other.

Johnson & Johnson agreed to acquire Intra-Cellular Therapies Inc., a company focused on treatments for central nervous system ...